Rituximab is at least as effective as cyclophosphamide in inducing remission in people with ANCA-associated vasculitis (AAV), and it may offer a safer, more targeted option for many patients, according to a review study. “These findings reinforce the evolving role of rituximab…
Rituximab matches cyclophosphamide in inducing AAV remission: Review
This article was provided by our partner, the American Partnership for Eosinophilic Disorders (APFED). It has been reviewed by Bionews for accuracy and relevance. The views and opinions expressed are those of the author and do not necessarily reflect the views of Bionews or ANCA Vasculitis News. When…
Inflammation markers calculated from routine blood tests, such as ratios of different types of immune cells and a combined inflammation index, appear to increase when ANCA-associated vasculitis (AAV) is more active, a study found. Even though these markers are not specific to AAV, they “may serve as potential supportive…
Recently, I was talking with friends about navigating life after an accident that left one of them with post-concussive syndrome. Both are, without question, among the smartest people I know — and I’m not being effusive. Yet that single event transformed their lives in ways that feel profoundly familiar to…
A study linked high levels of a blood protein called CXCL6 with lung disease in people with ANCA-associated vasculitis (AAV), pointing to the protein as a potential biomarker to diagnose the condition and monitor its progression. Data indicate that people with AAV who have inflammatory lung disease tend to…
As I’ve been sharing, I’m preparing for a hip replacement. And, as is often the case with ANCA vasculitis, nothing about this process has been simple or straightforward. After a thoughtful and thorough conversation with the pre-surgery team, we made the decision to move my surgery back. Why should…
More than one-third of patients with newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) already have serious heart disease, a study found. The research also identified coronary artery spasms, sudden episodes of tightening in the heart’s blood vessels that reduce blood flow and can mimic a heart attack, as…
The first participant with ANCA-associated vasculitis (AAV) has been dosed in a Phase 1 clinical trial testing prulacabtagene leucel (prula-cel, formerly ADI-001), Adicet Bio’s experimental CAR T-cell therapy, in people with autoimmune diseases. All seven disease groups in the Phase 1 trial (NCT06375993) are now actively enrolling participants at…
Winter feels different when you have ANCA vasculitis. That’s especially true for me, because I recently moved to Michigan after living in the desert for 25 years. I’m still learning how to navigate real Midwestern winters and am far from mastering it yet. The shorter days, cold weather, and…
Tavneos (avacopan), in combination with standard treatment, induced disease remission within six months in nearly all adults with ANCA-associated vasculitis (AAV), according to pooled results from 16 published real-world studies. Real-world remission rates with Tavneos at six months and one year were higher than those reported in the…
Recent Posts
- Using the spoon theory to manage my energy with chronic illness
- FDA proposes removing Tavneos from market over data concerns
- Testing iron protein in blood may improve AAV monitoring and care
- Even with ANCA vasculitis, we can be awe-struck by our own bodies
- Current adult AAV criteria better at classifying the disease in children